Preliminary findings were presented at the 2025 ASCO Genitourinary Cancers Symposium. 2 Investigators reported that 71% of ...

Although it may take time for physicians to become used to this regimen, there is greater urgency now that it can be given ...

First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...

FDA approval targets NRG1 fusion–positive advanced cholangiocarcinoma, expanding biomarker-driven options beyond more common FGFR2 and IDH1 alterations. Zenocutuzumab delivered a 36.8% ORR in the ...

Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or ...

Dr Roberto Borea explores how BMI impacts NSCLC survival and molecular pathways, revealing key T-cell and redox data for IO ...

Distinct Biology Driving Different Treatment Needs: Advances in genomic profiling reveal that pediatric leukemias are ...

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

Allogeneic HSCT is frequently complicated by acute GVHD (~50%) and chronic GVHD (30%–70%), with steroid-refractory disease representing a major unmet need despite ruxolitinib availability. CK0802 ...

In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in ...

Sabari, MD, discusses the depth and durability of response to zongertinib in patients with HER2 mutation–positive non–small ...